GH stock forecast, quote, news & analysis
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use... Show more
Guardant Health (GH) Stock Analysis: Regulatory Milestones and Guideline Wins Drive Wall Street Upgrades
Key Takeaways
- Guardant Health shares have moved approximately 8% over the last 30 days, consolidating after a powerful rally that has seen the stock more than triple from its 52-week low.
- The American Cancer Society's inclusion of the Shield blood test in its updated colorectal cancer screening guidelines represents a landmark commercial catalyst.
- Multiple major Wall Street firms—including Goldman Sachs, RBC Capital, and Evercore ISI—initiated or upgraded coverage in June 2026 with price targets ranging from $150 to $185.
- FDA approval of Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS further solidifies the company's therapy selection franchise.
- First-quarter 2026 revenue of $301.66 million surpassed consensus estimates by 8.1%, reinforcing the company's growth trajectory toward profitability.
Current Market Snapshot
Guardant Health stock has entered a period of consolidation near the upper end of its 52-week range, trading between approximately $119 and $134 over the past 30 days. The shares have retreated modestly from their 52-week high of $135.00 reached in mid-June, reflecting normal profit-taking after an extraordinary rally. The broader healthcare and precision oncology sector has benefited from renewed investor interest in companies with clear regulatory pathways and expanding reimbursement coverage. Guardant's market capitalization now stands near $17.4 billion, underscoring the market's conviction in the company's long-term growth story across screening, therapy selection, and recurrence monitoring.
Guardant Health (GH) Business Overview and Competitive Position
Guardant Health is a precision oncology company headquartered in Palo Alto, California, that develops and commercializes blood-based liquid biopsy tests for cancer detection and management. The company's product portfolio spans three core franchises: Shield, the first and only FDA-approved blood test for primary colorectal cancer screening in average-risk adults aged 45 and older; Guardant360, a comprehensive genomic profiling test that helps oncologists match patients with advanced cancer to targeted therapies; and Reveal, a molecular residual disease test for monitoring recurrence in early-stage cancer patients. Guardant also provides tissue-based testing and real-world data analytics services to biopharmaceutical partners. The company competes with other liquid biopsy and diagnostic firms such as Exact Sciences, Natera, and Illumina, but its FDA-approved blood-based screening test and growing companion diagnostic indications provide meaningful competitive differentiation.
Recent Developments Driving GH
The most significant recent catalyst for Guardant Health arrived on May 26, 2026, when the American Cancer Society updated its colorectal cancer screening guidelines to include the Shield blood test as a recommended option for patients who decline or have not completed stool-based or visual examination screening. This endorsement, following the National Comprehensive Cancer Network's earlier guideline inclusion, positions Shield to reach the more than 50 million eligible Americans who remain unscreened. On June 10, 2026, the FDA approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, marking the 27th CDx indication globally for the platform and expanding its utility in non-small cell lung cancer. Earlier in the quarter, the company activated its strategic collaboration with Quest Diagnostics, making Shield available through Quest's nationwide network of nearly 650,000 clinician accounts and approximately 2,000 patient service centers. These regulatory and commercial developments triggered a wave of analyst actions in June 2026: RBC Capital initiated coverage with an Outperform rating and $185 price target, Goldman Sachs launched coverage with a Buy rating and $165 target, Evercore ISI upgraded the stock to Outperform with a $160 target, and Wolfe Research assumed coverage with an Outperform rating. The company's Q1 2026 earnings report on May 7 also contributed to positive sentiment, with revenue growing to $301.66 million and an EPS beat against consensus estimates.
Trending AI Robots
For investors seeking data-driven insights beyond traditional fundamental analysis, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots. Tickeron's platform hosts hundreds of AI robots that actively trade thousands of tickers across diverse strategies, timeframes, and risk profiles. Only the most consistently relevant and high-performing bots appear in the Trending section, allowing users to observe which algorithms are currently generating the strongest signals. These bots employ technical analysis, pattern recognition, and proprietary machine learning models to identify potential trading opportunities. Whether you are monitoring Guardant Health or exploring opportunities across the broader market, the Trending AI Robots page provides a window into how artificial intelligence is being applied to real-time trading decisions.
2026 Outlook and What Investors Should Watch
Looking ahead, several key factors will shape Guardant Health's trajectory through the remainder of 2026. The commercial ramp of Shield following ACS and NCCN guideline inclusions will be closely monitored, particularly as the Quest Diagnostics partnership scales and primary care physician awareness grows. The anticipated launch of the company's tumor-informed molecular residual disease test represents another potential growth catalyst. Investors should also watch for a potential update to U.S. Preventive Services Task Force guidelines, which could further expand Shield's addressable market. On the financial front, analysts project full-year 2026 revenue of approximately $1.31 billion, representing roughly 34% growth year-over-year, with the company continuing to narrow its path toward profitability. Competitive dynamics in the liquid biopsy space, reimbursement developments from commercial payers, and additional companion diagnostic approvals for Guardant360 CDx will also influence the stock's performance. Macroeconomic factors affecting the biotechnology sector, including interest rate expectations and healthcare policy developments, remain relevant background considerations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsMomentum Indicator for GH turns positive, indicating new upward trend
GH saw its Momentum Indicator move above the 0 level on June 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned positive. In of the 78 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GH just turned positive on June 26, 2026. Looking at past instances where GH's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 183 cases where GH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GH broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GH's P/B Ratio (60.976) is slightly higher than the industry average of (12.440). P/E Ratio (0.000) is within average values for comparable stocks, (145.998). GH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.492). GH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (15.175) is also within normal values, averaging (7.264).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of diagnostic technologies to improve cancer management
Industry MedicalSpecialties